<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854371</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2015-3375</org_study_id>
    <nct_id>NCT02854371</nct_id>
  </id_info>
  <brief_title>Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI</brief_title>
  <official_title>Evaluation of Hepatic Function Using Gd-EOB-DTPA Enhanced Liver Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Foundation of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver function is a key factor that can help predict the clinical outcome in patients with
      cirrhosis. Traditionally, liver function was measured using either indocyanine green (ICG) or
      other radionucleotides. Recently, gadoxetic acid has been reported to show liver function in
      several studies. There have been several approaches to measure liver function using gadoxetic
      acid, and hepatocyte fraction is one of the promising methods. Since gadoxetic acid enhanced
      liver MRI is clinically used world widely, it would be valuable if we can measure liver
      function using hepatocyte fraction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>gadoxetic acid MRI and ICG R15 test</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver function assessed by hepatocyte fraction</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>hepatocyte fraction obtained by T1 map sequence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function assessed by ICG R15 test</measure>
    <time_frame>3 days after MRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocyte uptake rate</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>calculated hepatic uptake rate from T1 map sequence at MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver stiffness value (kPa)</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>liver stiffness from MR elastography</description>
  </other_outcome>
  <other_outcome>
    <measure>Spleen stiffness value (kPa)</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>spleen stiffness from MR elastography</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse effect after contrast media administration</measure>
    <time_frame>within an hour after contrast media administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>adverse effect after ICG administration</measure>
    <time_frame>within an hour after ICG administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T2* value (msec)</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>T2 star value obtained from Dixon sequence before and after contrast media administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Bile duct excretion of contrast media on hepatobiliary phase</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>five point scale (1: no visualization, 5: opacification of 2nd branch~CBD)</description>
  </other_outcome>
  <other_outcome>
    <measure>ADC</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>apparent diffusion coefficient from DWI sequence using multiple b-values (0~800sec/mm2)</description>
  </other_outcome>
  <other_outcome>
    <measure>D</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>true diffusion coefficient from DWI sequence using multiple b-values (0~800sec/mm2)</description>
  </other_outcome>
  <other_outcome>
    <measure>D*</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>pseudodiffusion coefficient from DWI sequence using multiple b-values (0~800sec/mm2)</description>
  </other_outcome>
  <other_outcome>
    <measure>f</measure>
    <time_frame>1 month after MRI</time_frame>
    <description>perfusion fraction (%) from DWI sequence using multiple b-values (0~800sec/mm2)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>CLD and LC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoxetic acid enhanced liver MRI</intervention_name>
    <description>Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.
Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution.</description>
    <arm_group_label>CLD and LC</arm_group_label>
    <other_name>Primovist</other_name>
    <other_name>Eovist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICG R15</intervention_name>
    <description>ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.</description>
    <arm_group_label>CLD and LC</arm_group_label>
    <other_name>Indocyanine green retention test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with chronic liver disease or liver cirrhosis

          -  clinically scheduled for gadoxetic acid enhanced liver MRI

          -  signed informed consent

        Exclusion Criteria:

          -  under 18 years

          -  transarterial chemoembolization, radiation therapy for liver or bile duct within 2
             weeks

          -  systemic chemotherapy within 6 weeks

          -  any contraindication for contrast enhanced MRI

          -  hepatic iron deposition at prior imaging

          -  bile duct obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>July 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gadoxetic acid</keyword>
  <keyword>T1 map</keyword>
  <keyword>MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

